Green Cross Medical Science (GCMS) announced on Nov. 28 that it has obtained a U.S. patent on technology for detecting influenza viruses. This is the first time that GCMS has obtained a patent in the United States.
The patent involves technology for detecting influenza viruses through a multi-influenza diagnostic kit. By collecting and diagnosing phlegm and throat secretions from the human body, the technology can discriminate various types of influenza viruses such as AB, H1N1 and H3N2.
GCMS explained that it has proved its technological competitiveness in the multi-influenza diagnosis sector by acquiring the U.S. patent.
GCMS launched the GENEDIA Multi-influenza Ag Rapid Test, a rapid influenza antigen test, in 2014, which is based on its influenza virus detection technology. The product is currently exported to Mexico and Malaysia.